FindTrial
Sign In

Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections

Phase III Clinical Study on ART-123 in patients with disseminated intravascular coagulation (DIC) directly caused by malignant hematopoietic tumors or infections

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220059
Enrollment
Unknown
Registered
2005-09-08
Start date
2005-09-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disseminated intravascular coagulation (DIC)

Interventions

investigational material(s) Generic name etc : ART-123 INN of investigational material : Therapeutic category code : 333 Anticoagulants Dosage and Administration for Investigational material : Intrav

Sponsors

ASAHIKASEI PHARMA CORPORATION
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: -Patients given a diagnosis of DIC -Patients with malignant hematopoietic tumors or infections as the underlying diseases which directly caused DIC -Inpatients -Without distinction of sex, etc. Exclusion criteria: -Children under 15, etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026